The sleep apnea specialist's fourth-quarter results surpassed expectations.Inspire Medical Systems (INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, announced impressive fourth-quarter results on Feb. 10. Earnings per share (EPS) came in at $1.15, well ahead of the $0.73 consensus estimate. Revenue climbed to $239.7 million, exceeding the forecast of $236 million. MetricQ4 2024Q4 2024 Analysts' EstimateQ4 2023% ChangeEPS (diluted)$1.15$0.73$0.49134.7%Revenue$239 ...

Core Insights - Inspire Medical Systems (INSP) reported revenue of $239.72 million for the quarter ended December 2024, marking a year-over-year increase of 24.5% and exceeding the Zacks Consensus Estimate of $239.62 million by 0.04% [1] - The company achieved an EPS of $1.15, significantly higher than the $0.49 reported a year ago, resulting in an EPS surprise of 55.41% compared to the consensus estimate of $0.74 [1] Financial Performance - Inspire's stock has returned -10% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2.1% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3] Operational Metrics - Inspire opened 72 new U.S. Medical Centers, surpassing the average estimate of 59 by four analysts [4] - The total number of U.S. Medical Centers reached 1,435, slightly above the average estimate of 1,430 [4] - The company established 12 new U.S. sales territories, which is below the average estimate of 13 by three analysts [4] - The total number of U.S. sales territories stands at 335, marginally below the average estimate of 336 [4]

Inspire Medical Systems (INSP) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.41%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post earnings of $0.06 per share when it actually produced earnings of $0.60, delivering a surpri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

A Inspire. Inspire Medical Systems, Inc. JP Morgan Healthcare Conference January 13, 2025 NYSE: INSP © 2024 Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL. Inspire is a public company and has an Insider Trading Policy. The content in this deck is not to be shared with anybody outside of Inspire Medical Disclaimer From our entrepreneurial beginnings, and with a focus on delivering life-changing outcomes, we've been enhancing the lives of patients for over 17 years… >90,000 Patients tr ...

MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024. Recent Business Highlights and Full Year 2025 Guidance Generated revenue of $239.7 million for the fourth quarter of 2024, a 25% increase over the same quarter last ...

In its upcoming report, Inspire Medical Systems (INSP) is predicted by Wall Street analysts to post quarterly earnings of $0.74 per share, reflecting an increase of 51% compared to the same period last year. Revenues are forecasted to be $239.62 million, representing a year-over-year increase of 24.5%.The consensus EPS estimate for the quarter has been revised 23.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial ...

The market expects Inspire Medical Systems (INSP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 10, 2025, might help the stock move higher if these ...

Financial Performance - Preliminary Q4 2024 revenues estimated between $239.5 million and $239.7 million, up 25% YoY, surpassing Zacks Consensus Estimate of $233 million [2] - Full-year 2024 revenues estimated between $802.6 million and $802.8 million, up 28% from 2023, exceeding Zacks Consensus Estimate of $796.1 million [5] - 2025 revenue guidance projected between $940 million and $955 million, reflecting 17-19% growth over 2024, with Zacks Consensus Estimate at $949.4 million [6] Business Expansion - Activated 72 new US medical centers in Q4 2024, bringing total to 1,435 centers implanting Inspire therapy [3] - Created 12 new US sales territories in Q4 2024, increasing total to 335 territories [3] - Implemented new organizational structure to fuel growth, including leadership team expansion [4] Product Development - Soft launched Inspire V neurostimulator in Q4 2024, with over 40 implants completed in Singapore and the US [7] - Introduced SleepSync programming system in Q3 2024, with full US availability expected in 2024 [12] Market Performance - Shares plunged 13.4% at yesterday's closing despite robust preliminary results [1] - Shares lost 11.4% between Oct 1 and Dec 31, 2024, compared to industry's 4.9% decline and S&P 500's 3.7% gain [10] Industry Comparison - Cencora (COR) gained 0.2% against industry's 12.7% decline between Oct 1 and Dec 31, 2024 [11] - Boston Scientific (BSX) rallied 6.2% against industry's 4.1% decline between Oct 1 and Dec 31, 2024 [14] - Cardinal Health (CAH) gained 7.2% compared to industry's 0.8% growth between Oct 1 and Dec 31, 2024 [16]

Financial Performance - Revenue for Q4 2024 is anticipated to be in the range of $239.5 million to $239.7 million, a 25% increase over Q4 2023 [6] - Revenue for full year 2024 is expected to be between $802.6 million and $802.8 million, a 28% increase over full year 2023 [6] - Initial full year 2025 revenue guidance is projected to be in the range of $940 million to $955 million, representing a 17% to 19% increase over full year 2024 [3] Business Highlights - Activated 72 new centers in the U.S. in Q4 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy [6] - Created 12 new sales territories in the U.S. in Q4 2024, increasing the total to 335 U.S. sales territories [6] - Initiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S. [6] Organizational Changes - Jason Kelly appointed as Chief Manufacturing and Quality Officer effective January 20, 2025, bringing 10 years of experience from Stryker Corporation [3] - Carlton Weatherby expanded role to Chief Strategy and Growth Officer, leading U.S. Sales, Marketing, and Strategy teams [4] - Randy Ban transitioned to EVP, Patient Access and Therapy Development, focusing on enhancing patient outcomes and access to Inspire therapy [5] - Ivan Lubogo moved to SVP, Strategic Sales, leading a new team focused on Integrated Delivery Networks and strategic accounts [7] - Joe Sander promoted to SVP U.S. Sales, leveraging over 20 years of sales management experience [8] Leadership and Strategy - The company implemented a new organizational structure to drive continued growth and advance the adoption of Inspire therapy [6] - The leadership changes are aimed at fueling growth, enhancing patient outcomes, and expanding market reach [3][4][5][7][8] Market and Product Development - Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for moderate to severe obstructive sleep apnea [11] - The company is focused on expanding its leadership team and enhancing its commercial strategy to capitalize on growth opportunities [3][4]